Johnson & Johnson, Kaken Pharmaceutical Strike Licensing Agreement for the STAT6 Program That Targets Autoimmune, Allergic Diseases

Posted on by admin

Under terms of the deal, Johnson & Johnson will gain an exclusive license to the STAT6 program, with Kaken maintaining commercialization rights in Japan.

Leave a Reply

Your email address will not be published. Required fields are marked *